Beijing Balance Medical Technology Co., Ltd.

MediWound's NexoBrid Receives Marketing Authorization in Australia, Expanding Global Burn Treatment Access

- Australia's Therapeutic Goods Administration has granted marketing authorization for NexoBrid, an innovative enzymatic therapy for burn treatment in both adult and pediatric patients. - The approval brings NexoBrid's global authorization to 45 countries worldwide, reinforcing its recognition as a new standard of care in burn management. - Commercial launch is expected in the fourth quarter of 2025 through exclusive partner Balance Medical, supported by MediWound's manufacturing expansion completion by year-end 2025. - The milestone opens opportunities for broader Asia-Pacific region expansion, where growing demand exists for advanced wound and burn treatments.